TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02721160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition PBF
Description: Nutrition PBF focuses on children under five years old. It follows the standard PBF model in Burundi and combines quantitative indicators to encourage an increase in service delivery (see Table below) and qualitative indicators. Quality of nutrition activities is assessed quarterly, and a bonus or penalty is applied to subsidies received by the facilities according to their quality score.~Table: Incentivized indicators~CHW level~* nb of cases screened and referred to HC for acute malnutrition (AM)~* nb of classes promoting good nutrition~HC level~* nb of cases screened and cared for severe and moderate AM~* nb of growth follow-ups~Hospital level~* nb of treated severe AM cases with complications~* length of the stay~All hospitals with nutrition services fall under the Nutrition PBF program. At lower levels, only HCs in the intervention group and the CHW that refer to them are subject to the Nutrition PBF.
Study: NCT04755790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point Digit
Description: Patient is fit with Point Digit partial hand prosthetic system
Study: NCT02542904

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mesenteric excision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mesenteric excision
Study: NCT01862003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 400 mg/m2 (IV bolus) of Fluorouracil on day 1 of each 2-weekly cycle, to be given after completion of Irinotecan and Folinic acid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 2400 mg/m2 (IV) continuous infusion of Fluorouracil given over 46 hours - infusion to start after 5FU bolus.
Study: NCT00590317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prochlorperazine
Description: Patients receiving Prochlorperazine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Patients receiving Ondansetron
Study: NCT01628016

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: a word dot-probe task for training procedure
Description: In the word dot-probe task for training procedure of attention bias modification, 90% of the targets appeared at the neutral word position and 10% at the sad word position.In the placebo condition, the targets appeared with equal probability in the sad (50%) and neutral (50%) word positions.All participants in ABM and placebo conditions received eight 12-min training sessions over a 2-week period.During each session, participants completed 216 word dot-probe trials.
Study: NCT04550793

Intervention type: DRUG
Intervention: Botulinum toxin injection
Description: Botulinum toxin injection at affected brachialis and/or biceps brachials.
Study: NCT01976819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TW speaking valve/HME
Description: The TW speaking valve with HME will be used during the day, whereas during sleep patients will use an HME without an automatic speaking valve. Data from TW15 and TW22 will be combined.
Study: NCT01986218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986115
Study: NCT02155374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary advice
Description: Dietary advice to avoid food products with high glycemic index / high glucose load

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary advice
Description: Dietary advice to avoid food products with high glycemic index / high glucose load
Study: NCT01986218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986115
Study: NCT06552442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: High-dose intracoronary glucocorticoid methylprednisolone to abrogate no-reflow: a unique study for restoration of infarct-related artery patency and reduction of ischemia-reperfusion injury
Study: NCT01446952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E δ-Tocotrienol
Description: The first cohort will be dosed with δ-tocotrienol at 200 mg. A minimum of 3 participants is planned for each dosing cohort with Vitamin E δ-Tocotrienol dose escalation dependent on safety from prior cohorts.
Study: NCT04502810

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-level laser therapy
Description: Nd:Yag 1064 nm pulsed high-level Laser will be applied to the vulvar area.

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: High-level laser therapy
Description: Nd:Yag 1064 nm pulsed high-level Laser will be applied to the vulvar area.
Study: NCT02096861

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P13
Description: CT-P13 (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CT-P13
Description: CT-P13 (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P13
Description: CT-P13 (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Remicade
Description: Remicade (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Remicade
Description: Remicade (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Remicade
Description: Remicade (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose
Study: NCT02155374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose lowering medication
Description: Regular glucose lowering medication as prescribed by the patient's own physician before study entry

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose lowering medication
Description: Regular glucose lowering medication as prescribed by the patient's own physician before study entry

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy (containing glucocorticoids) as prescribed by the patient's own physician

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy (containing glucocorticoids) as prescribed by the patient's own physician
Study: NCT04540055

Intervention type: PROCEDURE
Intervention: Paravertebral block
Description: The subjects in this group received general anesthesia and USG-guided paravertebral block

Intervention type: PROCEDURE
Intervention: General Anesthesia
Description: The subjects in this group underwent MRM under routine general anesthesia without peripheral nerve block supplementation.
Study: NCT02898103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous peripheral nerve stimulation
Description: Active electrical stimulation for 5 minutes in the recovery room

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous peripheral nerve stimulation
Description: Active electrical stimulation for 5 minutes in the recovery room

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham stimulation
Description: Sham (placebo) stimulation for 5 minutes in the recovery room

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham stimulation
Description: Sham (placebo) stimulation for 5 minutes in the recovery room

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous peripheral nerve stimulation
Description: Active electrical stimulation for 2-4 weeks at home

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous peripheral nerve stimulation
Description: Active electrical stimulation for 2-4 weeks at home
Study: NCT03988517

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: timing of receiving the drug
Description: each group took levothyroxine in different timing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: timing of receiving the drug
Description: each group took levothyroxine in different timing
Study: NCT04733209

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TENS, US, exercise
Description: Physiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS, US, exercise
Description: Physiotherapy
Study: NCT02382367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood tests (Alpha-1 antitrypsin protein measurement, elastase-inhibitory capacity of plasma measurement, phenotypic and genotypic studies)
Study: NCT02488031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Error-reduction
Description: During this time participants will use a novel, custom designed computer interface to perform goal-directed movements with each leg in a 3D virtual environment designed to emphasize accurate movements. Leg movement will be detected using the LeapMotion sensor and we will quantify time endpoint errors by comparing the timing of the foot trajectory and the required time to target.~The error-reduction intervention will be a 4-week home-based program. Each participant will train 4 days a week for approximately 1 hours per day. Within a week, the task difficulty will increase by changing the presentation of the targets to be more unpredictable and by increasing movement speed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: International Cooperative Ataxia Rating Scale
Description: The ICARS is an assessment of the ataxia severity. The ICARS score is the total sum of the sub scores on specific movements and ranges from 0 to 100, with a score of 100 being indicative of the most severely affected outcome.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: International Cooperative Ataxia Rating Scale
Description: The ICARS is an assessment of the ataxia severity. The ICARS score is the total sum of the sub scores on specific movements and ranges from 0 to 100, with a score of 100 being indicative of the most severely affected outcome.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scale for the Assessment and Rating of Ataxia
Description: The SARA is an assessment of the ataxia severity. The SARA score is the total sum of the sub scores on specific movements and ranges from 0 to 100, with a score of 100 being indicative of the most severely affected outcome.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scale for the Assessment and Rating of Ataxia
Description: The SARA is an assessment of the ataxia severity. The SARA score is the total sum of the sub scores on specific movements and ranges from 0 to 100, with a score of 100 being indicative of the most severely affected outcome.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory, 2nd Ed
Description: This is a 21 question self-report inventory for measuring severity of depression.
Study: NCT00312286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 851B
Description: 851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
Study: NCT02488031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory, 2nd Ed
Description: This is a 21 question self-report inventory for measuring severity of depression.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroop
Description: This test measures selective attention and cognitive flexibility through reading aloud of color names or color of the print.
Study: NCT00312286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 851B
Description: 851B 1.5% formulation, gel, topically, twice a week for 1 cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 851B
Description: 851B 1.5% formulation, gel, topically, twice a week for 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 851B
Description: 851B 3.0% formulation, gel, topically, once a week for 1 cycle.
Study: NCT02488031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroop
Description: This test measures selective attention and cognitive flexibility through reading aloud of color names or color of the print.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Purdue Pegboard
Description: This test consists of a series of timed hand coordination and dexterity tasks.
Study: NCT00312286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 851B
Description: 851B 3.0% formulation, gel, topically, once a week for 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 851B
Description: 851B 3.0% formulation, gel, topically, twice a week for 1 cycle.
Study: NCT02488031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Purdue Pegboard
Description: This test consists of a series of timed hand coordination and dexterity tasks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Test of Attention
Description: A cognitive test assessing focus and attention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Test of Attention
Description: A cognitive test assessing focus and attention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6-minute Walk
Description: This test consists on a timed 6-minute walk test to evaluate how much distance is covered.
Study: NCT00312286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 851B
Description: 851B 3.0% formulation, gel, topically, twice a week for 2 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 851B
Description: 851B placebo-matching gel, topically, once a week for 1 cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 851B
Description: 851B placebo-matching gel, topically, twice a week for 1 cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 851B
Description: 851B placebo-matching gel, topically, once a week for 2 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 851B
Description: 851B placebo-matching gel, topically, twice a week for 2 cycles.
Study: NCT02456129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: single oral doses of 4 mg tablet Vilaprisan, administered once without the comedication of ITZ (period 1) and once with the comedication of ITZ (period 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] Vilaprisan
Description: an intravenous microtracer dose of \[14C\]Vilaprisan administered together with the 1st single oral dose of Vilaprisan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Itraconazole(ITZ)
Description: Itraconazole(ITZ) 200 mg as solution, once daily for 14 days
Study: NCT04958603

Intervention type: PROCEDURE
Intervention: L type release surgery
Description: Lateral release of the lateral support belt
Study: NCT00189137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ifosfamide and doxorubicin vs gemcitabine and docetaxel
Description: Arm 1 will consist of the two drug combination of doxorubicin and ifosfamide (with mesna) Treatment will be delivered over 3 days at 21 day intervals. Patients will receive filgrastim days 4-10 or peg-filgrastim on day 4 as a myeloid growth factor.~Arm 2 will consist of the two drug combination of gemcitabine (day 1, 8) and docetaxel (day 8) repeated at 21 day intervals. Patients will receive filgrastim as a myeloid growth factor days 9-15 or peg-filgrastim on day 4.~All patients will receive 4 cycles of chemotherapy unless there is unacceptable toxicity or disease progression that may adversely impact the surgical plan for complete resection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide and doxorubicin vs gemcitabine and docetaxel
Description: Arm 1 will consist of the two drug combination of doxorubicin and ifosfamide (with mesna) Treatment will be delivered over 3 days at 21 day intervals. Patients will receive filgrastim days 4-10 or peg-filgrastim on day 4 as a myeloid growth factor.~Arm 2 will consist of the two drug combination of gemcitabine (day 1, 8) and docetaxel (day 8) repeated at 21 day intervals. Patients will receive filgrastim as a myeloid growth factor days 9-15 or peg-filgrastim on day 4.~All patients will receive 4 cycles of chemotherapy unless there is unacceptable toxicity or disease progression that may adversely impact the surgical plan for complete resection.
Study: NCT01238887

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline Cellulose placebo pill
Description: Participants will be given gelatin capsules containing the placebo (microcrystaline cellulose) and will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. This will equal 3000 mg/day of the placebo contents. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Garcinia cambogia-derived hydroxycitric acid (2800 mg/day)
Description: The hydroxycitric acid treatment is derived from garcinia cambogia and is provided by the company, Glykon Technologies. In this condition, participants will receive HCA at a dosage of 2,800 mg/day in the form of gelatin capsules. Participants will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Garcinia cambogia-derived hydroxycitric acid (2800 mg/day)
Description: The hydroxycitric acid treatment is derived from garcinia cambogia and is provided by the company, Glykon Technologies. In this condition, participants will receive HCA at a dosage of 2,800 mg/day in the form of gelatin capsules. Participants will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Garcinia Cambogia derived Hydroxycitric Acid
Description: The hydroxycitric acid treatment is derived from garcinia cambogia and is provided by the company, Glykon Technologies. In this condition, participants will receive HCA at a dosage of 5,400 mg/day in the form of gelatin capsules. Participants will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Garcinia Cambogia derived Hydroxycitric Acid
Description: The hydroxycitric acid treatment is derived from garcinia cambogia and is provided by the company, Glykon Technologies. In this condition, participants will receive HCA at a dosage of 5,400 mg/day in the form of gelatin capsules. Participants will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
Study: NCT04281667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Antibiotics
Description: Oral antibiotics (neomycin 1g and metronidazole 1g at 3pm and 11pm the day before surgery)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral placebos (placebo 1 and placebo 2 at 3pm and 11pm the day before surgery)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Bowel Preparation
Description: Mechanical Bowel Preparation using 2L polyethylene glycol (Moviprep)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mechanical Bowel Preparation
Description: Mechanical Bowel Preparation using 2L polyethylene glycol (Moviprep)
Study: NCT00832013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: See detailed description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: See detailed description
Study: NCT00688168

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires measuring pain and other symptoms, mood, and quality of life.
Study: NCT01018602

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vildagliptin
Description: 100 mg per day over 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: inactive pill
Description: 1 pill per day over 24 months
Study: NCT03410654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus, Extended Release, (Envarsus Xr)
Description: After conversion of tacrolimus immediate release to tacrolimus extended release.
Study: NCT00949975

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD9668
Description: 2 x 30 mg oral tablets twice daily (bid) for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD9668
Description: 2 x 10 mg oral tablets twice daily (bid) for 12 weeks
Study: NCT02488031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6-minute Walk
Description: This test consists on a timed 6-minute walk test to evaluate how much distance is covered.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand Grip Dynamometer
Description: This tests measures hand grip strength.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand Grip Dynamometer
Description: This tests measures hand grip strength.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment
Description: This test is used to assess cognitive abilities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment
Description: This test is used to assess cognitive abilities.
Study: NCT04023019

Intervention type: BIOLOGICAL
Intervention: Nuwiq
Description: Nuwiq is a recombinant FVIII concentrate from a human cell line. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
Study: NCT00949975

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD9668
Description: 2 x 2.5 mg oral tablets twice daily (bid) for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD9668 Placebo
Description: 2 x Matched placebo to oral tablet twice daily (bid) for 12 weeks
Study: NCT02488031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Performance Function
Description: This test consists of a series of physical activities used to evaluate speed, coordination, and ease of movement.
Study: NCT00309088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral